Abstract
We report a case of developing multiple adenocarcinoma foci in multiple hyperplastic polyps in a patient with Helicobacter pylori infection and hypergastrinemia during long-term proton pump inhibitor (PPI) therapy. A 57-year-old man, who was undergoing hemodialysis for chronic renal failure, underwent an upper gastrointestinal endoscopy to elucidate the cause of anemia. Atrophic gastritis with H. pylori infection and multiple adenocarcinoma foci in multiple hyperplastic polyps were found in the endoscopic and histological examinations. Enterochromaffin-like micronests and parietal cell protrusion in the background of the polyps suggested the existence of hypergastrinemia. The serum gastrin level was markedly high—10,206 pg/ml (normal range 37–172 pg/ml). The cause of this marked hypergastrinemia was not autoimmune gastritis and gastrinoma. After discontinuing PPI therapy and successful eradication of H. pylori, the serum gastrin level decreased to normal range. These findings indicate that hypergastrinemia may be caused by long-term PPI therapy in patients with H. pylori infection. This case suggests that hypergastrinemia may mediate gastric carcinogenesis in patients with H. pylori infection.
Similar content being viewed by others
References
Goddard AF, Badreldin R, Pritchard DM, et al. British Society of Gastroenterology. The management of gastric polyps. Gut. 2010;59:1270–6.
Abraham SC, Singh VK, Yardley JH, et al. Hyperplastic polyps of the stomach: associations with histologic patterns of gastritis and gastric atrophy. Am J Surg Pathol. 2001;25:500–7.
Ohkusa T, Miwa H, Hojo M, et al. Endoscopic, histological and serologic findings of gastric hyperplastic polyps after eradication of Helicobacter pylori: comparison between responder and non-responder cases. Digestion. 2003;68:57–62.
Ginsberg GG, Al-Kawas FH, Fleischer DE, et al. Gastric polyps: relationship of size and histology to cancer risk. Am J Gastroenterol. 1996;91:714–7.
Daibo M, Itabashi M, Hirota T. Malignant transformation of gastric hyperplastic polyps. Am J Gastroenterol. 1987;82:1016–25.
Rattan J, Arber N, Tiomny E, et al. Gastric polypoid lesions—an 8-year study. Hepatogastroenterology. 1993;40:107–9.
Dirschmid K, Platz-Baudin C, Stolte M. Why is the hyperplastic polyp a marker for the precancerous condition of the gastric mucosa? Virchows Arch. 2006;448:80–4.
Orlowska J, Jarosz D, Pachlewski J, et al. Malignant transformation of benign epithelial gastric polyps. Am J Gastroenterol. 1995;90:2152–9.
Hizawa K, Fuchigami T, Iida M, et al. Possible neoplastic transformation within gastric hyperplastic polyp. Application of endoscopic polypectomy. Surg Endosc. 1995;9:714–8.
Zea-Iriarte WL, Sekine I, Itsuno M, et al. Carcinoma in gastric hyperplastic polyps. A phenotypic study. Dig Dis Sci. 1996;41:377–86.
Cristallini EG, Ascani S, Bolis GB. Association between histologic type of polyp and carcinoma in the stomach. Gastrointest Endosc. 1992;38:481–4.
Harju E. Gastric polyposis and malignancy. Br J Surg. 1986;73:532–3.
Shaib YH, Rugge M, Graham DY, et al. Management of gastric polyps: an endoscopy-based approach. Clin Gastroenterol Hepatol. 2013;11:1374–84.
Dacha S, Razvi M, Massaad J, et al. Hypergastrinemia. Gastroenterol Rep (Oxf). 2015;3:201–8.
Warrington S, Baisley K, Boyce M, et al. Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects. Aliment Pharmacol Ther. 2002;16:1301–7.
Solcia E, Bordi C, Creutzfeldt W, et al. Histopathological classification of nonantral gastric endocrine growths in man. Digestion. 1988;41:185–200.
Bordi C, D’Adda T, Azzoni C, et al. Pathogenesis of ECL cell tumors in humans. Yale J Biol Med. 1998;71:273–84.
Furumoto K, Kojima H, Okuno M, et al. Gastric carcinoid with hypergastrinemia: report of three cases. Case Rep Med. 2010. doi:10.1155/2010/348761.
Jianu CS, Fossmark R, Viset T, et al. Gastric carcinoids after long-term use of a proton pump inhibitor. Aliment Pharmacol Ther. 2012;36:644–9.
Fossmark R, Qvigstad G, Waldum HL. Gastric cancer: animal studies on the risk of hypoacidity and hypergastrinemia. World J Gastroenterol. 2008;21(14):1646–51.
Fossmark R, Qvigstad G, Martinsen TC, et al. Animal models to study the role of long-term hypergastrinemia in gastric carcinogenesis. J Biomed Biotechnol. 2011. doi:10.1155/2011/975479.
Waldum HL, Hauso Ø, Sørdal ØF, et al. Gastrin may mediate the carcinogenic effect of helicobacter pylori infection of the stomach. Dig Dis Sci. 2015;60:1522–7.
Tsukashita S, Kushima R, Bamba M, et al. MUC gene expression and histogenesis of adenocarcinoma of the stomach. Int J Cancer. 2001;94:166–70.
Nishimura R, Mukaisho K, Yamamoto H, et al. Precursor-derived versus de-novo carcinogenesis depends on lineage-specific mucin phenotypes of intramucosal gland-forming gastric neoplasms. Histopathology. 2013;63:616–29.
Little SE, Vuononvirta R, Reis-Filho JS, et al. Array CGH using whole genome amplification of fresh-frozen and formalin-fixed, paraffin-embedded tumor DNA. Genomics. 2006;87:298–306.
Vo DT, Nakayama T, Yamamoto H, et al. Progression risk assessments of individual non-invasive gastric neoplasms by genomic copy-number profile and mucin phenotype. BMC Med Genom. 2015. doi:10.1186/s12920-015-0080-6.
Barrett MT, Scheffer A, Ben-Dor A, et al. Comparative genomic hybridization using oligonucleotide microarrays and total genomic DNA. Proc Natl Acad Sci USA. 2004;101:17765–70.
Stolte M, Bethke B, Seifert E, et al. Observation of gastric glandular cysts in the corpus mucosa of the stomach under omeprazole treatment. Z Gastroenterol. 1995;33:146–9.
Stolte M, Bethke B, Rühl G, et al. Omeprazole-induced pseudohypertrophy of gastric parietal cells. Z Gastroenterol. 1992;30:134–8.
Thomson AB, Sauve MD, Kassam N, et al. Safety of the long-term use of proton pump inhibitors. World J Gastroenterol. 2010;21(16):2323–30.
Montemurro NE, Di Maggio A, Loperfido A, et al. Effects of omeprazole therapy on peptic disease and serum gastrin levels in hemodialysis patients. A preliminary study. Clin Nephrol. 1993;40:296–8.
Eslami L, Nasseri-Moghaddam S. Meta-analyses: does long-term PPI use increase the risk of gastric premalignant lesions? Arch Iran Med. 2013;16:449–58.
Song H, Zhu J, Lu D. Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions. Cochrane Database Syst Rev. 2014. doi:10.1002/14651858.
Hagiwara T, Mukaisho K, Nakayama T, et al. Long-term proton pump inhibitor administration worsens atrophic corpus gastritis and promotes adenocarcinoma development in Mongolian gerbils infected with Helicobacter pylori. Gut. 2011;60:624–30.
Hongo M, Fujimoto K, Gastric Polyps Study Group. Incidence and risk factor of fundic gland polyp and hyperplastic polyp in long-term proton pump inhibitor therapy: a prospective study in Japan. J Gastroenterol. 2010;45:618–24.
Jianu CS, Lange OJ, Viset T, et al. Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor. Scand J Gastroenterol. 2012;47:64–7.
Yamauchi H, Sakurai S, Nakazawa N, et al. A case of mixed adenoneuroendocrine carcinoma of the stomach with focal intestinal metaplasia and hypergastrinemia. Int Surg. 2015;100:562–7.
McGuigan JE, Trudeau WL. Serum and tissue gastrin concentrations in patients with carcinoma of the stomach. Gastroenterology. 1973;64:22–5.
Fossmark R, Sagatun L, Nordrum IS, et al. Hypergastrinemia is associated with adenocarcinomas in the gastric corpus and shorter patient survival. APMIS. 2015;123:509–14.
Lauwers GY, Wahl SJ, Melamed J, et al. p53 expression in precancerous gastric lesions: an immunohistochemical study of PAb 1801 monoclonal antibody on adenomatous and hyperplastic gastric polyps. Am J Gastroenterol. 1993;88:1916–9.
Nogueira AM, Carneiro F, Seruca R, et al. Microsatellite instability in hyperplastic and adenomatous polyps of the stomach. Cancer. 1999;86:1649–56.
Murakami K, Mitomi H, Yamashita K, et al. p53, but not c-Ki-ras, mutation and down-regulation of p21WAF1/CIP1 and cyclin D1 are associated with malignant transformation in gastric hyperplastic polyps. Am J Clin Pathol. 2001;115:224–34.
Buffart TE, van Grieken NC, Tijssen M, et al. High resolution analysis of DNA copy-number aberrations of chromosomes 8, 13, and 20 in gastric cancers. Virchows Arch. 2009;455:213–23.
Kang JU. Chromosome 8q as the most frequent target for amplification in early gastric carcinoma. Oncol Lett. 2014;7:1139–43.
Hattori T. Morphological range of hyperplastic polyps and carcinomas arising inhyperplastic polyps of the stomach. J Clin Pathol. 1985;38:622–30.
Kushima R, Vieth M, Borchard F, et al. Gastric-type well-differentiated adenocarcinoma and pyloric gland adenoma of the stomach. Gastric Cancer. 2006;9:177–84.
Kushima R, Hattori T. Histogenesis and characteristics of gastric-type adenocarcinomas in the stomach. J Cancer Res Clin Oncol. 1993;120:103–11.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest:
Hajime Anjiki, Ken-ichi Mukaisyo, Yu Kadomoto, Hisakazu Doi, Yoshikawa Kunio, Takahisa Nakayama, Diem Thi-Ngoc Vo, Hattori Takanori and Sugihara Hiroyuki declare that they have no conflict of interest.
Human Rights:
All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
Informed Consent:
Informed consent was obtained from all patients for being included in the study.
Rights and permissions
About this article
Cite this article
Anjiki, H., Mukaisho, Ki., Kadomoto, Y. et al. Adenocarcinoma arising in multiple hyperplastic polyps in a patient with Helicobacter pylori infection and hypergastrinemia during long-term proton pump inhibitor therapy. Clin J Gastroenterol 10, 128–136 (2017). https://doi.org/10.1007/s12328-017-0714-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12328-017-0714-7